OQP Bio's Bio Business Progresses Smoothly... Increased Expectations for Phase 3 Clinical Trial of Ovarian Cancer Treatment

[Asia Economy Reporter Jang Hyowon] On the 21st, the industry reported that the global Phase 3 clinical trial of OQP Bio's ovarian cancer immunotherapy drug 'Oregobomab' is progressing smoothly.

Oregobomab showed results in a Phase 2 clinical trial combining it with existing chemotherapy agents (paclitaxel or carboplatin), where progression-free survival (PFS) was extended by about 30 months compared to conventional chemotherapy.

OQP Bio is conducting the Phase 3 clinical trial at 106 sites across 11 countries globally, including the United States, Canada, Spain, and Italy, through IQVIA, the world's number one contract research organization. In particular, in the United States, the Phase 3 trial is being conducted at 65 major sites including Mount Sinai Hospital in New York, University of Wisconsin Hospital, Duke University Gynecologic Oncology Center, and Yale University School of Pharmacy Hospital.

Moreover, clinical trials are also underway at six hospitals in South Korea: Bundang Seoul National University Hospital, Asan Medical Center, Korea University Anam Hospital, Yonsei Severance Hospital, Catholic St. Mary's Hospital, and National Cancer Center.

An OQP Bio official stated, "The global Phase 3 clinical trial of the ovarian cancer treatment Oregobomab is progressing without any setbacks," and added, "Starting with the global Phase 3 trial of Oregobomab, OQP Bio plans to sequentially develop its new drug pipeline, including pancreatic cancer and metastatic breast cancer."

OQP Bio is a corporation established following the spin-off of 'OQP' and holds the asset IP of OQP's bio business division. Recently, Duol Mulsan, registered on K-OTC, announced through a disclosure response that it plans to comprehensively acquire OQP Bio's bio assets through a subsidiary to be incorporated via a merger of the parent and subsidiary companies.